TSX:LABS - Post Discussion
Post by
mdjbrown on Jan 30, 2024 10:48am
At some point the cryptic nature of Medipharm press releases
will need to be explained by the company.
Here is an older release regarding Medipharm future growth in Mexico, and yet very little has been reported since.
https://enfarma.lat/index.php/noticias/4555-mexico-con-potencial-para-el-mercado-de-cannabis-medicinal-y-de-grado-farmaceutico-medipharm-labs Same goes for Brazil. Is Medipharm still in partnership with XLR8? Who are the other partners / customers?
"
In July 2023, the Company entered into an additional supply agreement with a top tier generic pharmaceutical company in Brazil. Brazilian authorities treat cannabis much like a pharmaceutical product. Since signing the agreement the customer has applied to the Brazilian Health Regulatory Agency for a number of cannabis product approvals. MediPharm has received similar approvals in Brazil with other customers. It is anticipated the delivery of additional products could begin in Q1 2024, and substantially increase the current Brazilian revenue" Mr. Strachan, it is apparent you read these shareholder communication blogs, so how about going beyond X and updating shareholders regularly?
Be the first to comment on this post